Lifecore Biomedical (LFCR) Stock: Buy, Sell, or Hold?
LFCR - Lifecore Biomedical, Inc. Common Stock
$6.42
0.00 (-0.08%)
âŧ
5d:
-0.39%
30d:
+54.95%
90d:
+29.6%
WAIT
LOW Confidence
Analysis Updated: Oct 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When LFCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LFCR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LFCR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: LFCR is currently trading at $6.42, which is considered slightly high relative to its 30-day fair value range of $4.24 to $6.45.
Technical Outlook: Technically, LFCR is showing sideways momentum. The price is currently testing key support at $6.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LFCR scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LFCR is showing sideways momentum. The price is currently testing key support at $6.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LFCR scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$4.24 -
$6.45
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (10/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($6.28)
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.24 -
$6.45
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$0.69
(10.7%)
Support & Resistance Levels
Support Level
$6.40
Resistance Level
$6.58
Current Trend
Sideways
Technical data as of
Oct 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.78
Wall Street Target
$6.28
(-2.2%)
Revenue Growth (YoY)
-3.8%
Profit Margin
-23.8%
Share & Embed Analysis
Last updated: October 14, 2026 2:57 PM ET
Data refreshes hourly during market hours. Next update: 3:57 PM
Data refreshes hourly during market hours. Next update: 3:57 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LFCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$207 | 53 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$57 | 64 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 54 HOLD |
|
AMLX
Amylyx Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$42 | 59 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 58 HOLD |
